• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

HYDERABAD: The Unit VIII facility of Aurobindo Pharma Ltd (APL) has received approvals from the United States Federal Drug Authority (USFDA) as a site to manufacture Active Pharmaceutical Intermediates (APIs) for the US market.

The Unit VIII of the Hyderabad-based APL consists of four production blocks, of which three are geared for APIs for regulated markets in the anti-retro virals CNS /anti-allergics / CVS segments.

This is the third approval for the company given by USFDA. The others being unit I for APIs and unit III for formulations. Unit VIII facility is situated at Gaddapotharam Village, Kazipally - IDA, Jinnaram (Mandal), Medak District, Andhra Pradesh.

APL has around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment. It markets these products globally in over 100 countries, according to a company press release today.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
RIL reduces prices of 7 products

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line